HK1207095A1 - Composition comprising a mixture of cd95-fc isoforms cd95-fc - Google Patents

Composition comprising a mixture of cd95-fc isoforms cd95-fc

Info

Publication number
HK1207095A1
HK1207095A1 HK15107778.6A HK15107778A HK1207095A1 HK 1207095 A1 HK1207095 A1 HK 1207095A1 HK 15107778 A HK15107778 A HK 15107778A HK 1207095 A1 HK1207095 A1 HK 1207095A1
Authority
HK
Hong Kong
Prior art keywords
isoforms
mixture
composition
Prior art date
Application number
HK15107778.6A
Other languages
English (en)
Chinese (zh)
Inventor
．黑爾
．傑弗斯
．斯爾曼
Original Assignee
Apogenix Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apogenix Gmbh filed Critical Apogenix Gmbh
Publication of HK1207095A1 publication Critical patent/HK1207095A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
HK15107778.6A 2012-07-18 2015-08-11 Composition comprising a mixture of cd95-fc isoforms cd95-fc HK1207095A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12176978 2012-07-18
EP12176980 2012-07-18
PCT/EP2013/065250 WO2014013039A1 (en) 2012-07-18 2013-07-18 Composition comprising a mixture of cd95-fc isoforms

Publications (1)

Publication Number Publication Date
HK1207095A1 true HK1207095A1 (en) 2016-01-22

Family

ID=48794121

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15107778.6A HK1207095A1 (en) 2012-07-18 2015-08-11 Composition comprising a mixture of cd95-fc isoforms cd95-fc
HK15107780.2A HK1207096A1 (en) 2012-07-18 2015-08-11 Shortened cd95-fc variants cd95-fc

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK15107780.2A HK1207096A1 (en) 2012-07-18 2015-08-11 Shortened cd95-fc variants cd95-fc

Country Status (18)

Country Link
US (5) US9315570B2 (de)
EP (4) EP2875045B1 (de)
JP (2) JP6317739B2 (de)
KR (1) KR102201694B1 (de)
CN (3) CN104640876A (de)
AU (2) AU2013291982B2 (de)
BR (1) BR112015000732B1 (de)
CA (2) CA2877989C (de)
DK (2) DK3409686T3 (de)
ES (2) ES2674662T3 (de)
HK (2) HK1207095A1 (de)
IL (1) IL236659A (de)
MX (1) MX371430B (de)
NZ (1) NZ703546A (de)
RU (2) RU2648157C2 (de)
SG (1) SG11201500134QA (de)
UA (1) UA116889C2 (de)
WO (2) WO2014013039A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3409686T3 (da) * 2012-07-18 2022-07-18 Apogenix Ag Sammensætning omfattende en blanding af cd95-fc-isoformer
AU2014261505B2 (en) * 2013-04-29 2019-04-18 Apogenix Ag Method of diagnosing cancer
NO2776305T3 (de) * 2014-04-23 2018-01-27
WO2015165973A1 (en) 2014-04-29 2015-11-05 Apogenix Gmbh Diagnostic anti-cd95l antibody
US9587215B2 (en) 2014-08-07 2017-03-07 General Electric Company Devices, systems and methods for automated transfer of a sample
JP6783767B2 (ja) * 2014-12-22 2020-11-11 アレクシオン ファーマシューティカルズ インコーポレイテッドＡｌｅｘｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 組換えタンパク質を精製する方法
EP3946437A1 (de) 2019-03-29 2022-02-09 Myst Therapeutics, LLC Ex-vivo-verfahren zur herstellung eines t-zell-therapeutikums und zugehörige zusammensetzungen und verfahren
WO2021108727A1 (en) 2019-11-27 2021-06-03 Myst Therapeutics, Inc. Method of producing tumor-reactive t cell composition using modulatory agents
JP2023506472A (ja) * 2019-12-12 2023-02-16 イー・エム・デイー・ミリポア・コーポレイシヨン 透析濾過緩衝液を用いて増強したウイルス濾過
CA3172902A1 (en) 2020-02-27 2021-09-02 Myst Therapeutics, Llc Methods for ex vivo enrichment and expansion of tumor reactive t cells and related compositions thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997042319A1 (fr) * 1996-05-02 1997-11-13 Mochida Pharmaceutical Co., Ltd. NOUVEAUX DERIVES DE L'ANTIGENE Fas
CA2270423C (en) * 1996-10-31 2009-09-15 Mochida Pharmaceutical Co., Ltd. Prophylactic/therapeutic agent
WO1998038304A1 (fr) * 1997-02-27 1998-09-03 Ono Pharmaceutical Co., Ltd. Nouveau polypeptide, adn le codant et utilisation de ce polypeptide
EP1029550A4 (de) * 1997-11-10 2001-09-26 Mochida Pharm Co Ltd Vorbeugende mittel und heilmittel gegen diffuse lungenkrankheiten
CA2433877C (en) * 2001-01-17 2014-11-18 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
EP1273297A1 (de) * 2001-07-06 2003-01-08 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Vitamin E für die Behandlung von Krankheiten in denen die Bindung des Transkriptionsfaktors NF-KB und/oder AP-1 an die Zielorte des Promotors einen günstigen Effekt hat (z.B. AIDS, Herzinfarkt)
JP4741464B2 (ja) * 2003-03-26 2011-08-03 アポゲニクス ゲゼルシャフト ミット ベシュレンクテル ハフツング 改良したＦｃ融合タンパク質
AU2007231553B2 (en) * 2006-03-28 2012-10-25 Molecular Discovery Systems Agent for the treatment of hormone-dependent disorders and uses thereof
BRPI0713484A2 (pt) * 2006-06-21 2012-11-06 Apogenix Gmbh expressão diferencial de citocina em cáncer humano
ES2420582T3 (es) * 2006-12-28 2013-08-26 Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts La neutralización de la actividad de CD95 bloquea la invasión de células de glioblastoma in vivo
WO2008101671A2 (en) * 2007-02-19 2008-08-28 Apogenix Gmbh Il-4 fc fusion proteins
EP2009022A1 (de) * 2007-06-26 2008-12-31 Apogenix GmbH Trimere Todesliganden mit erhöhter Aktivität (Tenascin)
EP2540740B1 (de) * 2008-06-17 2014-09-10 Apogenix GmbH Multimere TNF-Rezeptoren
JP5844158B2 (ja) * 2009-01-09 2016-01-13 アポゲニクス ゲゼルシャフト ミット ベシュレンクテル ハフツングＡｐｏｇｅｎｉｘ ＧｍｂＨ 三量体形成融合タンパク質
US11369572B2 (en) * 2009-07-21 2022-06-28 Queen Mary & Westfield College Fas (Apo-1,CD95) targeted platforms for intracellular drug delivery
JP2013512674A (ja) * 2009-12-02 2013-04-18 アクセルロン ファーマ， インコーポレイテッド Ｆｃ融合タンパク質の血清半減期を増加させるための組成物および方法
DK3409686T3 (da) * 2012-07-18 2022-07-18 Apogenix Ag Sammensætning omfattende en blanding af cd95-fc-isoformer
AU2014261505B2 (en) * 2013-04-29 2019-04-18 Apogenix Ag Method of diagnosing cancer

Also Published As

Publication number Publication date
EP2875045B1 (de) 2018-03-28
US20160235815A1 (en) 2016-08-18
EP3406630A1 (de) 2018-11-28
CN104640876A (zh) 2015-05-20
US20180186856A1 (en) 2018-07-05
US20150225475A1 (en) 2015-08-13
UA116889C2 (uk) 2018-05-25
CN109897115A (zh) 2019-06-18
CA2878992A1 (en) 2014-01-23
HK1207096A1 (en) 2016-01-22
WO2014013039A1 (en) 2014-01-23
RU2648157C2 (ru) 2018-03-22
ES2674662T3 (es) 2018-07-03
US9908928B2 (en) 2018-03-06
SG11201500134QA (en) 2015-03-30
MX371430B (es) 2020-01-30
BR112015000732A2 (de) 2017-08-15
EP2875044A1 (de) 2015-05-27
RU2015105328A (ru) 2016-09-10
MX2015000731A (es) 2015-09-04
JP2015528006A (ja) 2015-09-24
CN104662039B (zh) 2019-10-08
EP2875045A1 (de) 2015-05-27
DK3409686T3 (da) 2022-07-18
US9657083B2 (en) 2017-05-23
AU2013291984B2 (en) 2018-01-18
BR112015000732B1 (pt) 2023-01-10
IL236659A (en) 2017-02-28
EP3406630B1 (de) 2020-09-02
KR20150048120A (ko) 2015-05-06
US10370441B2 (en) 2019-08-06
JP2015524403A (ja) 2015-08-24
CA2878992C (en) 2020-09-22
AU2013291984A1 (en) 2015-02-05
US20150166633A1 (en) 2015-06-18
EP3409686A1 (de) 2018-12-05
NZ703546A (en) 2018-03-23
DK2875045T3 (en) 2018-07-02
CN104662039A (zh) 2015-05-27
WO2014013037A1 (en) 2014-01-23
KR102201694B1 (ko) 2021-01-12
IL236659A0 (en) 2015-02-26
US20160362471A1 (en) 2016-12-15
CA2877989A1 (en) 2014-01-23
JP6317739B2 (ja) 2018-04-25
US9315570B2 (en) 2016-04-19
RU2648146C2 (ru) 2018-03-22
AU2013291982A1 (en) 2015-02-05
AU2013291982B2 (en) 2017-01-12
ES2924109T3 (es) 2022-10-04
EP2875044B1 (de) 2018-04-11
JP6231562B2 (ja) 2017-11-15
US9434783B2 (en) 2016-09-06
CA2877989C (en) 2021-05-25
RU2015105330A (ru) 2016-09-10
EP3409686B1 (de) 2022-04-13

Similar Documents

Publication Publication Date Title
HK1212701A1 (zh) 恩雜魯胺製劑
HK1213798A1 (zh) 治療性化合物和組合物
HK1210041A1 (en) Compositions comprising mixtures of semifluorinated alkanes
EP2709972A4 (de) Nichtentflammbare zusammensetzungen aus chlor-trifluorpropen
HK1207095A1 (en) Composition comprising a mixture of cd95-fc isoforms cd95-fc
EP2855550A4 (de) Polyurethanfugenmassen
EP2917314A4 (de) Oligomeratzusammensetzung
HK1216503A1 (zh) 用於經皮傳遞安非他命的組合物及方法
HK1210709A1 (en) Composition for external use
HK1216250A1 (zh) '- '-羥基-二氫麥角胺化合物及組合物
GB201200707D0 (en) Composition
EP2878295A4 (de) Zusammensetzung
EP2769718A4 (de) Medizinische zusammensetzung
IL236312A0 (en) Preparation of 18f-flucyclobin
EP2867199A4 (de) Stabile zusammensetzungen aus fesoterodin
GB201420971D0 (en) Therapeutic composition
HK1207558A1 (en) Propynylaminoindan transdermal compositions
ZA201402166B (en) Compositions of efavirenz
EP2837670A4 (de) Fluorbiphenylhaltige zusammensetzung
IL217807A0 (en) Therapeutic compositions
EP2938431A4 (de) Herstellung einer aluminiumoxid-silikazusammensetzung
EP2910537A4 (de) Zusammensetzung mit einem gaserzeugenden mittel
EP2910538A4 (de) Zusammensetzung eines gaserzeugungsmittels
GB201218355D0 (en) Surfacing mixture
EP2702991A4 (de) Zusammensetzung von entacopon